Immunovant, INC Form 4 insider transactions

Immunovant CEO Peter Salzmann sold 16,692 shares of common stock to cover tax obligations following the vesting of restricted stock units.

Immunovant's Chief Operating Officer, Melanie Gloria, was granted stock options and restricted stock units as part of her compensation.

Mark S. Levine, Chief Legal Officer of Immunovant, Inc., sold 4,361 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Michael Geffner, Immunovant's Chief Medical Officer, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Jay S. Stout, Chief Technology Officer of Immunovant, Inc., sold 2,740 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Immunovant CEO Peter Salzmann sold 9,095 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

William L. Macias, Chief Medical Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Mark S. Levine, Chief Legal Officer of Immunovant, Inc., sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Eva Renee Barnett, CFO of Immunovant, Inc., sold 3,271 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Eva Renee Barnett, CFO of Immunovant, Inc., sold 5,162 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Immunovant CEO Peter Salzmann sold 4,460 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Mark S. Levine, Chief Legal Officer of Immunovant, Inc., reports the sale of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

William L. Macias, Chief Medical Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Eva Renee Barnett, CFO of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Julia G. Butchko, Chief Development Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Immunovant CEO Peter Salzmann sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Jay S. Stout, Immunovant's Chief Technology Officer, sold 2,813 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Michael Geffner, Immunovant's Chief Medical Officer, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Mark S. Levine, Chief Legal Officer of Immunovant, Inc., sold 4,015 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Mark S. Levine, Chief Legal Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

William L. Macias, Chief Medical Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Eva Renee Barnett, CFO of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Julia G. Butchko, Chief Development Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Immunovant CEO Peter Salzmann sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Eva Renee Barnett, CFO of Immunovant, Inc., sold 4,747 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Julia G. Butchko, Chief Development Officer of Immunovant, Inc., sold 1,527 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Immunovant CEO Peter Salzmann sold 4,619 shares of common stock on July 9, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Eva Renee Barnett, CFO of Immunovant, Inc., sold 4,042 shares of common stock on May 22, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Immunovant CEO Peter Salzmann sold 16,163 shares of common stock on May 22, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Julia G. Butchko, Chief Development Officer of Immunovant, Inc., sold shares to cover tax withholding obligations related to the vesting of restricted stock units.